<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02574156</url>
  </required_header>
  <id_info>
    <org_study_id>SDC</org_study_id>
    <nct_id>NCT02574156</nct_id>
  </id_info>
  <brief_title>Control of Hyperglycemia After Cardiac Surgery: CHyCS Trial</brief_title>
  <acronym>CHyCS</acronym>
  <official_title>Control of Hyperglycemia After Cardiac Surgery: CHyCS Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Sao Paulo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>InCor Heart Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Sao Paulo</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators aim to study the impact of a strategy of a intensive glycemic control in
      patients undergoing cardiac surgery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients undergoing heart surgery at the Heart Institute (InCor) will be randomized and in
      accordance with a list of random numbers, generated by a computer program, are allocated in
      one of the treatment groups (conventional or intensive) when the blood glucose value recorded
      is greater than 200 mg/dl on two consecutive measures in an interval of 30
      minutes.Conventional Group (GCon): patients randomized to the conventional group will receive
      insulin infusion in a dilution of 100 units of regular insulin in 100 ml of physiological
      solution (NaCl 0.9%) in continuous infusion pump for maintenance of blood glucose between 140
      mg/dl and 180 mg/dl.

      Group intensive (GInt): patients randomized to the intensive group will receive insulin
      infusion in a dilution of 100 units of regular insulin in 100 ml of physiological solution
      (NaCl 0.9%) in continuous infusion pump for maintenance of blood glucose between 90 mg/dl and
      110 mg/dl.

      The insulin dose adjustment will be based on measurements of arterial blood glucose
      undiluted, held at intervals of one to 4 hours with the use of a monitoring system of glucose
      and beta-blood ketone (Freestyle Precision Pro, Abbott). The dosage is adjusted according to
      an algorithm by a team of intensive care nurses, trained for this purpose and assisted by a
      study physician not involved in the clinical care of patients.

      On admission, all patients will receive intravenous glucose solution continuously (200 to 300
      g in 24 hours). As soon as possible, the patient will be nurtured according to the routine of
      Surgical ICU for nutrition in the postoperative period of cardiac surgery patient.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2017</start_date>
  <completion_date type="Anticipated">December 20, 2018</completion_date>
  <primary_completion_date type="Anticipated">August 1, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Infection of surgical wound infection</measure>
    <time_frame>30 days</time_frame>
    <description>The primary outcome measure will be assessed according to the American Society of Thoracic Surgeons guidelines</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Need for reoperation</measure>
    <time_frame>30 days</time_frame>
    <description>This outcome measure will be assessed according to the American Society of Thoracic Surgeons guidelines</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute renal injury (defined by the KDIGO classification)</measure>
    <time_frame>30 days</time_frame>
    <description>This outcome measure will be assessed according to the KDIGO Criterion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Infection of the bloodstream</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prolonged mechanical ventilation</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need for transfusion of blood products</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrences of hypoglycemia</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Hyperglycemia</condition>
  <arm_group>
    <arm_group_label>Conventional Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients randomized for Conventional Group will receive insulin infusion of regular insulin (100 UI) in 100 mL of saline in continuous infusion pump for maintenance of blood glucose between 140 mg/dl and 180 mg/dl.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Moderate Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients randomized for ModerateGroup will receive insulin infusion of regular insulin (100 UI) in 100 mL of saline in continuous infusion pump for maintenance of blood glucose between 100 mg/dl and 130 mg/dl.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin</intervention_name>
    <description>All patients will receive insulin. However, the infusion flow will be different according to the group.</description>
    <arm_group_label>Conventional Group</arm_group_label>
    <arm_group_label>Moderate Group</arm_group_label>
    <other_name>Glycemic Control</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients undergoing heart surgery;

          -  Age greater than 18 years;

          -  Sign the informed consent form;

          -  Capillary blood glucose greater than 200mg/dL ICU admission

        Exclusion Criteria:

          -  Admitted for surgical repair of congenital heart defects;

          -  Dialytic Chronic renal failure;

          -  Participation in other research protocol;

          -  Diagnosis of HIV/AIDS;

          -  Pregnant.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eduesley Santana Santos, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Sao Paulo</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Eduesley Santana-Santos, Ph.D</last_name>
    <phone>11986912250</phone>
    <email>eduesley@oi.com.br</email>
  </overall_contact>
  <location>
    <facility>
      <name>Eduesley Santana Santos</name>
      <address>
        <city>São Paulo</city>
        <zip>01307-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eduesley Santana-Santos, Ph.D</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <results_reference>
    <citation>Macrae D, Grieve R, Allen E, Sadique Z, Morris K, Pappachan J, Parslow R, Tasker RC, Elbourne D; CHiP Investigators. A randomized trial of hyperglycemic control in pediatric intensive care. N Engl J Med. 2014 Jan 9;370(2):107-18. doi: 10.1056/NEJMoa1302564. Erratum in: N Engl J Med. 2014 Apr 10;370(15):1469.</citation>
    <PMID>24401049</PMID>
  </results_reference>
  <results_reference>
    <citation>Yates AR, Dyke PC 2nd, Taeed R, Hoffman TM, Hayes J, Feltes TF, Cua CL. Hyperglycemia is a marker for poor outcome in the postoperative pediatric cardiac patient. Pediatr Crit Care Med. 2006 Jul;7(4):351-5.</citation>
    <PMID>16738506</PMID>
  </results_reference>
  <results_reference>
    <citation>NICE-SUGAR Study Investigators, Finfer S, Chittock DR, Su SY, Blair D, Foster D, Dhingra V, Bellomo R, Cook D, Dodek P, Henderson WR, Hébert PC, Heritier S, Heyland DK, McArthur C, McDonald E, Mitchell I, Myburgh JA, Norton R, Potter J, Robinson BG, Ronco JJ. Intensive versus conventional glucose control in critically ill patients. N Engl J Med. 2009 Mar 26;360(13):1283-97. doi: 10.1056/NEJMoa0810625. Epub 2009 Mar 24.</citation>
    <PMID>19318384</PMID>
  </results_reference>
  <results_reference>
    <citation>Brunkhorst FM, Engel C, Bloos F, Meier-Hellmann A, Ragaller M, Weiler N, Moerer O, Gruendling M, Oppert M, Grond S, Olthoff D, Jaschinski U, John S, Rossaint R, Welte T, Schaefer M, Kern P, Kuhnt E, Kiehntopf M, Hartog C, Natanson C, Loeffler M, Reinhart K; German Competence Network Sepsis (SepNet). Intensive insulin therapy and pentastarch resuscitation in severe sepsis. N Engl J Med. 2008 Jan 10;358(2):125-39. doi: 10.1056/NEJMoa070716.</citation>
    <PMID>18184958</PMID>
  </results_reference>
  <results_reference>
    <citation>Preiser JC, Devos P, Ruiz-Santana S, Mélot C, Annane D, Groeneveld J, Iapichino G, Leverve X, Nitenberg G, Singer P, Wernerman J, Joannidis M, Stecher A, Chioléro R. A prospective randomised multi-centre controlled trial on tight glucose control by intensive insulin therapy in adult intensive care units: the Glucontrol study. Intensive Care Med. 2009 Oct;35(10):1738-48. doi: 10.1007/s00134-009-1585-2. Epub 2009 Jul 28.</citation>
    <PMID>19636533</PMID>
  </results_reference>
  <results_reference>
    <citation>Dandona P, Mohanty P, Chaudhuri A, Garg R, Aljada A. Insulin infusion in acute illness. J Clin Invest. 2005 Aug;115(8):2069-72.</citation>
    <PMID>16075050</PMID>
  </results_reference>
  <results_reference>
    <citation>Boyle EM Jr, Pohlman TH, Johnson MC, Verrier ED. Endothelial cell injury in cardiovascular surgery: the systemic inflammatory response. Ann Thorac Surg. 1997 Jan;63(1):277-84. Review.</citation>
    <PMID>8993292</PMID>
  </results_reference>
  <results_reference>
    <citation>Shahian DM, O'Brien SM, Filardo G, Ferraris VA, Haan CK, Rich JB, Normand SL, DeLong ER, Shewan CM, Dokholyan RS, Peterson ED, Edwards FH, Anderson RP; Society of Thoracic Surgeons Quality Measurement Task Force. The Society of Thoracic Surgeons 2008 cardiac surgery risk models: part 3--valve plus coronary artery bypass grafting surgery. Ann Thorac Surg. 2009 Jul;88(1 Suppl):S43-62. doi: 10.1016/j.athoracsur.2009.05.055.</citation>
    <PMID>19559824</PMID>
  </results_reference>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 8, 2015</study_first_submitted>
  <study_first_submitted_qc>October 9, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 12, 2015</study_first_posted>
  <last_update_submitted>May 5, 2017</last_update_submitted>
  <last_update_submitted_qc>May 5, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Sao Paulo</investigator_affiliation>
    <investigator_full_name>Eduesley Santana Santos</investigator_full_name>
    <investigator_title>RN, Ph.D</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperglycemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

